Drug Utilization Review Board
Meeting Agenda
Thursday, August 13, 2026 7:15 a.m. to 8:30 a.m. Google Meet joining info
Video call link: meet.google.com/qbv-rjpz-fst
Or dial: (US) +1 314-474-3014 PIN: 334 496 072#
Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov at least one week prior to the meeting. A required conflict of interest form must be submitted by the Thursday before the meeting at 12 pm (Mountain Time). Public comments will be limited to 3 minutes per speaker or organization due to time constraints.
1) Call to order - Sharon Weinstein, MD
a) Welcome
b) Review and Approval of Minutes
2) Prior Authorization Updates - Luis Moreno, PharmD
3) Review Topic
a) Evidence and Guideline Recommendations on the Role of Esketamine (Spravato) for the Treatment of Bipolar Depression - Monet Luloh, PharmD
i) Board Discussion/Questions
4) Public Comment
5) Review Prior Authorization Criteria
a) Spravato (esketamine) nasal spray - Luis Moreno, PharmD
i) Board Discussion/Questions
ii) Board Action
b) Parathyroid Hormone Analogs (Bonsity, Evenity, Forteo, Tymlos, Yorvipath) - Kyu Yun Park, PharmD
i) Board Discussion/Questions
ii) Board Action
c) Tzield (teplizumab-mzwv) - Luis Moreno, PharmD
i) Board Discussion/Questions
ii) Board Action
6) Next Meeting
a) Date: September 10, 2026
b) Topic: New prior authorization form reviews
7) Adjourned - Sharon Weinstein, MD
Notice of Special Accommodations (ADA)
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at 801-538-6155 option 1, 1.
Notice of Electronic or Telephone Participation
Video call link: meet.google.com/qbv-rjpz-fst
Or dial: (US) +1 314-474-3014 PIN: 334 496 072#